Biogen announced mixed Phase 2 data for its Alzheimer's therapy diranersen, showing clinical decline slowing but raising questions about data robustness, leading to a significant stock drop. Separately, the company secured FDA approval for a weekly subcutaneous LEQEMBI injection, which is a positive development but overshadowed by the diranersen news.
Biogen's stock fell nearly 9% after presenting new Phase 2 data for its investigational Alzheimer's therapy, diranersen. While the data showed the drug slowed clinical decline and reduced tau biomarkers, an RBC Capital Markets analyst noted that the findings 'leave more questions than answers,' particularly regarding data robustness and the strongest clinical benefit being observed in the lowest-dose group despite higher doses showing greater tau reductions. This skepticism from analysts is a significant short-term negative catalyst for Biogen, as it casts doubt on the drug's future success despite its advancement to Phase 3. The simultaneous FDA approval for a weekly subcutaneous LEQEMBI injection, a positive for patient convenience and market access, was overshadowed by the diranersen concerns, highlighting the market's focus on pipeline drug development in the biotech sector.